Roche (RHHBY) announced the launch of a human papillomavirus self sampling solution in countries accepting the CE mark. This new solution enables a patient to privately collect her sample for HPV screening while at a healthcare facility. The vaginal sample is analysed with the Roche cobas HPV test on a Roche molecular instrument.
"Reducing barriers to HPV screening by enabling women to self-collect their own specimen for HPV testing is a critical tool in the fight against cervical cancer," said Thomas Schinecker, CEO Roche Diagnostics.
For comments and feedback contact: editorial@rttnews.com
Business News